FA
NEO icon

Friess Associates’s NeoGenomics NEO Stock Holding History

Friess Associates’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-199,931
Closed -$3.07M – 136
2018
Q3 		$3.07M Buy
+199,931
New +$2.76M 0.21% 92
2014
Q4 		– Sell
-50,000
Closed -$260K – 156
2014
Q3 		$260K Buy
+50,000
New +$257K 0.02% 98

Other funds holding NEO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ECM
Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Friess Associates's NEO Position: Q4 2018 in Review

Friess Associates sold out of NeoGenomics (NEO) in Q4 2018, closing a stake of 199,931 shares — an estimated $3.07M sold.

Friess Associates first reported a position in NEO in Q3 2014 and held it in 2 quarters. The position peaked at $3.07M in Q3 2018. 210 funds tracked by Wall St. Rank hold NEO as of Q4 2018.

  • Friess Associates reported no remaining NeoGenomics position as of Q4 2018 after selling out during the quarter.
  • Friess Associates sold 199,931 NeoGenomics shares in Q4 2018, an estimated $3.07M.
  • Friess Associates first reported a position in NeoGenomics in Q3 2014 and held it in 2 quarters.
  • Friess Associates's NeoGenomics position peaked at $3.07M in Q3 2018.
  • 210 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2018.

Based on Friess Associates's 13F filing for Q4 2018, filed 14 Feb 2019.